Alexander Muik

20PUBLICATIONS
103CO-AUTHORS
Innate immunityCancer therapy (excl. chemotherapy and radiation therapy)Evolution of developmental systemsAgricultural molecular engineering of nucleic acids and proteinsGenetically modified animals
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Oct 22, 2026
HexaBody-OX40 promotes antitumor immunity through FcγR crosslinking-independent OX40 agonist activity and enhances effects of PD-1 blocking antibodies.

|Sep 04, 2026
Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity.

|Dec 05, 2025
Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccines.

Wei Chen, Kristin R Tompkins, Ian W Windsor

|Nov 20, 2024
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine.

Kayvon Modjarrad, Ye Che, Wei Chen

|Nov 15, 2022
Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.

Alexander Muik, Bonny Gaby Lui, Maren Bacher

|Sep 20, 2022
Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5.

Alexander Muik, Bonny Gaby Lui, Maren Bacher

Pageof 4

Frequent Collaborators

14 joint publications

Ugur Sahin

9 joint publications

Kena A Swanson

8 joint publications

Pei-Yong Shi

6 joint publications

Mathias Vormehr